MCID: PNC008
MIFTS: 38

Pancreatic Endocrine Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Pancreatic Endocrine Carcinoma

MalaCards integrated aliases for Pancreatic Endocrine Carcinoma:

Name: Pancreatic Endocrine Carcinoma 12 15 73
Malignant Neoplasm of Islets of Langerhans 12
Pancreatic Neuroendocrine Carcinoma 12
Carcinoma of Endocrine Pancreas 12
Carcinoma, Islet Cell 44
Islet Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1798
ICD10 33 C25.4
ICD9CM 35 157.4
MeSH 44 D018273
NCIt 50 C3770
SNOMED-CT 68 60346004 93843007
UMLS 73 C1328479

Summaries for Pancreatic Endocrine Carcinoma

Disease Ontology : 12 An islet cell tumor that has material basis in epithelial cells.

MalaCards based summary : Pancreatic Endocrine Carcinoma, also known as malignant neoplasm of islets of langerhans, is related to somatostatinoma and islet cell tumor. An important gene associated with Pancreatic Endocrine Carcinoma is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Neuroscience and Cardiac Progenitor Differentiation. The drugs Levoleucovorin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and colon, and related phenotypes are behavior/neurological and nervous system

Related Diseases for Pancreatic Endocrine Carcinoma

Diseases related to Pancreatic Endocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
# Related Disease Score Top Affiliating Genes
1 somatostatinoma 32.5 INS SST
2 islet cell tumor 31.9 INS SST
3 multiple endocrine neoplasia, type i 29.9 INS SST SYP
4 carcinoid syndrome 29.9 SST SYP
5 neuroendocrine carcinoma of pancreas 11.3
6 zollinger-ellison syndrome 10.2
7 small cell carcinoma 10.2 NCAM1 SYP
8 esophageal neuroendocrine tumor 10.2 NCAM1 SYP
9 ovarian large-cell neuroendocrine carcinoma 10.2 NCAM1 SYP
10 lung combined type small cell carcinoma 10.2 NCAM1 SYP
11 gallbladder small cell carcinoma 10.2 NCAM1 SYP
12 cutaneous ganglioneuroma 10.2 NCAM1 SYP
13 ganglioneuroma 10.2 NCAM1 SYP
14 extrahepatic bile duct adenocarcinoma 10.2 NCAM1 SYP
15 orbital cancer 10.2 NCAM1 SYP
16 hypoganglionosis 10.2 NCAM1 SYP
17 endometrial small cell carcinoma 10.2 NCAM1 SYP
18 pancreatic serous cystadenoma 10.2 NCAM1 SYP
19 conventional angiosarcoma 10.2 NCAM1 SYP
20 supratentorial primitive neuroectodermal tumor 10.2 NCAM1 SYP
21 mediastinal cancer 10.2 NCAM1 SYP
22 angiomyoma 10.2 NCAM1 SYP
23 cervical clear cell adenocarcinoma 10.2 NCAM1 SYP
24 gastric small cell carcinoma 10.2 NCAM1 SYP
25 subependymoma 10.2 NCAM1 SYP
26 gastric squamous cell carcinoma 10.2 NCAM1 SYP
27 spermatocele 10.2 NCAM1 SYP
28 olfactory neuroblastoma 10.2 SSTR2 SYP
29 large cell neuroendocrine carcinoma 10.2 NCAM1 SYP
30 pancreatic ductal adenocarcinoma 10.2
31 malignant glandular tumor of peripheral nerve sheath 10.1 SST SYP
32 adenoma of the pancreas 10.1 SST SYP
33 pancreatic somatostatinoma 10.1 SST SYP
34 lung benign neoplasm 10.1 NCAM1 SYP
35 gastrointestinal neuroendocrine tumor 10.1 SST SYP
36 granulosa cell tumor of the ovary 10.1 INS SYP
37 type c thymoma 10.1 SST SSTR2
38 peripheral nervous system neoplasm 10.1 NCAM1 SYP
39 rubeosis iridis 10.1 INS SYP
40 pancreatoblastoma 10.1 SST SYP
41 functional colonic disease 10.1 SST SYP
42 large cell carcinoma 10.1 NCAM1 SYP
43 binswanger's disease 10.1 SST SYP
44 growth hormone secreting pituitary adenoma 10.1 SST SSTR2
45 orbital plasma cell granuloma 10.1 NCAM1 SST
46 malignant pheochromocytoma 10.1 SST SYP
47 colonic pseudo-obstruction 10.1 SST SYP
48 abdominal obesity-metabolic syndrome 1 10.1 INS MEG3
49 conn's syndrome 10.1
50 hyperinsulinism 10.1

Graphical network of the top 20 diseases related to Pancreatic Endocrine Carcinoma:



Diseases related to Pancreatic Endocrine Carcinoma

Symptoms & Phenotypes for Pancreatic Endocrine Carcinoma

MGI Mouse Phenotypes related to Pancreatic Endocrine Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.43 INS NCAM1 POMC SST SSTR2 SYP
2 nervous system MP:0003631 9.1 INS NCAM1 POMC SST SSTR2 SYP

Drugs & Therapeutics for Pancreatic Endocrine Carcinoma

Drugs for Pancreatic Endocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
6
Somatostatin Approved, Investigational Phase 2, Phase 3,Phase 1 51110-01-1, 38916-34-6 53481605
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
9 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1,Not Applicable
11 Vitamin B9 Phase 2, Phase 3
12 Immunologic Factors Phase 2, Phase 3,Phase 1
13 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
14 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1,Not Applicable
15 Folate Phase 2, Phase 3
16 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
17 Antimetabolites Phase 2, Phase 3,Phase 1,Not Applicable
18 Hormones Phase 2, Phase 3,Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
20 Hormone Antagonists Phase 2, Phase 3,Phase 1
21 Cola Phase 3,Phase 2,Phase 1
22 Central Nervous System Depressants Phase 3
23 Adjuvants, Anesthesia Phase 3
24 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
25 Anesthetics, Intravenous Phase 3
26 Analgesics, Opioid Phase 3
27 Peripheral Nervous System Agents Phase 3
28 Anesthetics, General Phase 3
29 Analgesics Phase 3
30 Narcotics Phase 3
31 Anesthetics Phase 3
32
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
33
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
34
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
35
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
36
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
37
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
38
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
39
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
40
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
41
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
42
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
43
Pancrelipase Approved, Investigational Phase 2,Not Applicable 53608-75-6
44
Melphalan Approved Phase 2 148-82-3 4053 460612
45
Sunitinib Approved, Investigational Phase 2,Not Applicable 557795-19-4, 341031-54-7 5329102
46
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
47
Etoposide Approved Phase 2 33419-42-0 36462
48
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
49
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
50
Nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer Completed NCT00781911 Phase 2 depot octreotide
5 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
6 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
7 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
8 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
9 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT02101918 Phase 2
10 Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT01169649 Phase 2 MK-2206
11 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
12 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
13 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
14 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
15 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
16 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
17 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
18 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
19 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
20 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
21 Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II Recruiting NCT02230176 Phase 2 Sunitinib;177Lu-DOTA0-Tyr3-Octreotate
22 Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer Recruiting NCT02820857 Phase 2 Folfiri-bevacizumab;Folfiri
23 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery Recruiting NCT02595424 Phase 2 Capecitabine;Carboplatin;Cisplatin;Etoposide;Temozolomide
24 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride
25 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
26 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
27 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
28 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
29 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
30 A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) Not yet recruiting NCT03591731 Phase 2 Nivolumab;Ipilimumab
31 Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin Not yet recruiting NCT03736720 Phase 2 Fluorouracil;Leucovorin;Liposomal Irinotecan
32 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Suspended NCT02893930 Phase 2 Sapanisertib
33 FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Terminated NCT03042780 Phase 2 FOLFIRINOX;Granulocyte colony-stimulating factor (G-CSF)
34 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
35 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
36 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
37 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
38 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
39 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
40 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
41 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
42 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
43 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
44 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
45 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
46 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
47 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
48 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
49 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
50 Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene Completed NCT00444795 Sunitinib malate;Sunitinib malate;sunitinib malate

Search NIH Clinical Center for Pancreatic Endocrine Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, islet cell

Genetic Tests for Pancreatic Endocrine Carcinoma

Anatomical Context for Pancreatic Endocrine Carcinoma

MalaCards organs/tissues related to Pancreatic Endocrine Carcinoma:

41
Pancreas, Lung, Colon, Pituitary, Thyroid, Cortex, Adrenal Gland

Publications for Pancreatic Endocrine Carcinoma

Articles related to Pancreatic Endocrine Carcinoma:

(show all 14)
# Title Authors Year
1
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. ( 27160433 )
2016
2
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. ( 21831734 )
2011
3
Pancreatic endocrine carcinoma protruding from the major papilla. ( 20144741 )
2010
4
A case of multiple hepatic metastases from pancreatic endocrine carcinoma. ( 18573853 )
2008
5
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. ( 18362846 )
2008
6
Successful pancreatectomy with en-bloc resection of the celiac artery and portal vein for pancreatic endocrine carcinoma. ( 17629086 )
2007
7
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. ( 16364959 )
2006
8
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. ( 17158766 )
2006
9
Somatostatin-producing pancreatic endocrine carcinoma presented as relapsing cholangitis -- a case report. ( 15849491 )
2005
10
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? ( 14962717 )
2004
11
Curative resection for a pancreatic endocrine carcinoma involving the portal vein. ( 15532841 )
2004
12
Pancreatic endocrine carcinoma with multiple hormone production in a raccoon (Procyon lotor). ( 10213674 )
1999
13
Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. ( 1322859 )
1992
14
Pancreatic endocrine carcinoma with ectopic PTH-production and paraneoplastic hypercalcaemia. ( 3082066 )
1986

Variations for Pancreatic Endocrine Carcinoma

Expression for Pancreatic Endocrine Carcinoma

Search GEO for disease gene expression data for Pancreatic Endocrine Carcinoma.

Pathways for Pancreatic Endocrine Carcinoma

Pathways related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.67 NCAM1 POMC SYP
2 10.35 INS NCAM1

GO Terms for Pancreatic Endocrine Carcinoma

Biological processes related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.65 INS POMC SST SSTR2 SSTR5
2 cell-cell signaling GO:0007267 9.54 INS POMC SST
3 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.4 SSTR2 SSTR5
4 glucose homeostasis GO:0042593 9.33 INS POMC SSTR5
5 cellular response to glucocorticoid stimulus GO:0071385 9.32 SSTR2 SSTR5
6 neuropeptide signaling pathway GO:0007218 9.13 POMC SSTR2 SSTR5
7 somatostatin signaling pathway GO:0038170 8.62 SSTR2 SSTR5

Molecular functions related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide binding GO:0042923 9.16 SSTR2 SSTR5
2 hormone activity GO:0005179 9.13 INS POMC SST
3 somatostatin receptor activity GO:0004994 8.62 SSTR2 SSTR5

Sources for Pancreatic Endocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....